

3002-2US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Chris M. FARNET et al.

Examiner: Kathleen M. Kerr

Serial No.: 09/976,059

Group Art Unit: 1652

Filed: October 15, 2001

Attorney docket no: 3002-2US

For: GENE CLUSTER FOR
RAMOPLANIN BIOSYNTHESIS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97(b)(3)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant submits, pursuant to 37 C.F.R. §§ 1.97 and 1.98, a form PTO-1449 with the references B1-B2 and C1-C6 listed thereon. Copies of references B1-B2 and C1-C6 are also submitted herewith.

The Hammond *et al.* (1982 J. Chem. Society) reference listed as C4 on the attached form PTO-1449 was previously cited as reference C-28 in the Information Disclosure Statement filed on or about January 11, 2002. However, a copy of the Hammond reference was not included with the January 11, 2002 Information Disclosure Statement, as it was considered substantially cumulative with other references cited, pursuant to 37 CFR 1.98(c). Nevertheless, for the sake of completeness and in an abundance of caution, a copy of the Hammond reference is submitted herewith.

Reference C5 submitted herewith is a copy of the slides from a presentation given by applicant/inventor Chris M. Farnet on October 17, 2000 at the Genetics and Molecular


Biology of Industrial Microorganisms (GMBIM) Conference 2000, sponsored by the Society for Industrial Microbiology, October 15-19, 2000 at Indiana University in Bloomington, IN.

It is respectfully requested that the examiner consider the cited references and that the references are made of record in the file of the present application.

Pursuant to 37 C.F.R §1.97(b)(3), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits; accordingly, no fee is believed to be due. However, in the event that the Patent Office determines that a fee is due, applicants authorize the Assistant Commissioner to charge required fee to Deposit Account No. 501784.

This Information Disclosure Statement is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or for the above information constitutes prior art to the subject invention.

Respectfully submitted,



Anne M. Coughlin
Reg. No. 43,564

Dated: February 26, 2004

ECOPIA BIOSCIENCES INC.
7290 Frederick-Banting
Saint-Laurent (Quebec) H4S 2A1
Canada
Tel. (514) 336-2700
Fax (514) 336-8827

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

3002-2US

Application Number

USSN 09/976,059

Applicant(s)

Chris M. Farnet et al.

Filing Date

October 15, 2001

Group Art Unit

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C3

Dockel S., Marahiel M.A., Metabolic Engineering, (2001) vol.3, pp.64-77
"Biosynthesis of natural products on modular peptide synthetases"

C4


Hammond, S.J. et al., J. Chem. Soc. Chem. Commun., (1982) pp.344-346
"On the biosynthesis of the antibiotic vancomycin"

C5

Ecopia BioSciences Inc., conference - October 17, 2000
"From Genes to Molecules"

C6

Marahiel M.A. et al., Chem. Rev., (1997) vol.97, pp.2651-2673
"Modular peptide synthetases involved in nonribosomal peptide synthesis"



EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.